RAPT Therapeutics (RAPT) Stock Forecast & Price Target

$1.10 -0.18 (-14.01%)

(As of 11/15/2024 ET)

RAPT Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 13 Analyst Ratings

Sell
1

Hold
10

Buy
2

Based on 13 Wall Street analysts who have issued ratings for RAPT Therapeutics in the last 12 months, the stock has a consensus rating of "Hold." Out of the 13 analysts, 1 has given a sell rating, 10 have given a hold rating, and 2 have given a buy rating for RAPT.

Consensus Price Target

$9.50
759.73% Upside

According to the 13 analysts' twelve-month price targets for RAPT Therapeutics, the average price target is $9.50. The highest price target for RAPT is $39.00, while the lowest price target for RAPT is $2.00. The average price target represents a forecasted upside of 759.73% from the current price of $1.11.

Get the Latest News and Ratings for RAPT and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for RAPT Therapeutics and its competitors.

RAPT Analyst Ratings Over Time

Type	Current Forecast 11/18/23 to 11/17/24	1 Month Ago 10/19/23 to 10/18/24	3 Months Ago 8/20/23 to 8/19/24	1 Year Ago 11/18/22 to 11/18/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	2 Buy rating(s)	1 Buy rating(s)	2 Buy rating(s)	9 Buy rating(s)
Hold	10 Hold rating(s)	9 Hold rating(s)	9 Hold rating(s)	0 Hold rating(s)
Sell	1 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$9.50	$18.17	$21.57	$37.20
Forecasted Upside	759.73% Upside	914.90% Upside	829.80% Upside	163.08% Upside
Consensus Rating	Hold	Hold	Hold	Buy

Unveiled: NVIDIA’s "Secret Royalty" Program (Ad)

Did you know that there's an investment that will give you the opportunity to collect "royalties" every time Nvidia makes a chip?

Click Here to learn how to get in now >>>

RAPT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

RAPT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

RAPT Therapeutics Stock vs. The Competition

Type	RAPT Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.08	2.80	2.50
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	759.73% Upside	28,534.46% Upside	9.87% Upside
News Sentiment Rating	Neutral News See Recent RAPT News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/13/2024	Stifel Nicolaus 4 of 5 stars		Reiterated Rating	Buy ➝ Hold	$7.00 ➝ $2.00	+14.94%
11/12/2024	Wells Fargo & Company 3 of 5 stars		Lower Target	Overweight ➝ Overweight	$17.00 ➝ $4.00	+124.72%
11/12/2024	HC Wainwright 2 of 5 stars		Reiterated Rating	Neutral
11/11/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	E. Tenthoff Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral	$8.00 ➝ $2.00	+20.48%
11/11/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Neutral ➝ Underweight
9/9/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$10.00 ➝ $2.00	+6.38%
Get the Latest News and Ratings for RAPT and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for RAPT Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
5/14/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Peer Perform
5/10/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Y. Suneja Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
5/10/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Overweight ➝ Equal Weight	$13.00 ➝ $4.00	-14.16%
2/21/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	T. Smith Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
2/21/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform	$42.00 ➝ $10.00	+45.56%
2/20/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	P. Agrawal Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral
2/16/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform
9/14/2023	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$34.00	+77.64%
3/15/2023	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy	$27.00 ➝ $23.00	+20.73%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 09:23 AM ET.

RAPT Forecast - Frequently Asked Questions

: According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for RAPT Therapeutics is $9.50, with a high forecast of $39.00 and a low forecast of $2.00.
: 13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for RAPT Therapeutics in the last twelve months. There is currently 1 sell rating, 10 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" RAPT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RAPT, but not buy additional shares or sell existing shares.
: According to analysts, RAPT Therapeutics's stock has a predicted upside of 759.73% based on their 12-month stock forecasts.
: Over the previous 90 days, RAPT Therapeutics's stock had 2 downgrades by analysts.
: RAPT Therapeutics has been rated by research analysts at HC Wainwright, JPMorgan Chase & Co., Piper Sandler, Stifel Nicolaus, UBS Group, and Wells Fargo & Company in the past 90 days.
: Analysts like RAPT Therapeutics less than other "medical" companies. The consensus rating for RAPT Therapeutics is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how RAPT compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

JD Vance Predicts: Wall Street vs. Trump & Your Money (Ad)

Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.

Get your free guide NOW before it's too late.

This page (NASDAQ:RAPT) was last updated on 11/17/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

RAPT Therapeutics (RAPT) Stock Forecast & Price Target